Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523887 | 0.86 | HRH3 (0.68) | HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL3774758 | 0.85 | HRH3 (0.63) | HRH3KCNH2SMN1; SMN2L3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL524379 | 0.85 | HRH3 (0.67) | HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL3768862 | 0.85 | HRH3 (0.48) | HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL24185708 | 0.85 | RAB9A (0.60) | HRH3KCNH2RAB9ASMN1; SMN2L3MBTL3 | |
| SCHEMBL3773373 | 0.84 | KDM4E (0.52) | HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL3774042 | 0.83 | HRH3 (0.49) | HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL13005941 | 0.83 | KDM4E (0.54) | HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL3765811 | 0.83 | KDM4E (0.54) | HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL13006111 | 0.83 | HRH3 (0.48) | HRH3L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | HRH3 2/4885KCNH2 130/4885RAB9A 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.